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ABSTRACT
Aortic stenosis (AS) and regurgitation (AR) may be treated with surgical aortic
valve replacement (SAVR), transcatheter AVR (TAVR), or medical therapy (MT). Data
are lacking regarding usage and cost of SAVR, TAVR, and MT for patients hospitalized
with aortic valve disease. From the Nationwide Readmissions Database, we determined
utilization and cost trends for SAVR, TAVR, and MT in patients with aortic valve disease
admitted 2012-2016 for valve replacement, heart failure, unstable angina, non-STelevation myocardial infarction, or syncope. From 2012 through 2016, there was a
48.1% increase in the number of patients hospitalized for aortic valve disease annually.
Overall, 19.9%, 6.7%, and 73.4% of patients received SAVR, TAVR, and MT,
respectively. SAVR decreased from 21.9% in 2012 to 18.5% in 2016; TAVR increased
from 2.6% to 12.5%; and MT decreased from 75.5% to 69.0%. In multivariable analysis,
likelihood of TAVR relative to SAVR increased 4.57-fold (95% confidence interval 4.214.97) with TAVR increasing at the expense of both SAVR and MT. The average 6month inpatient costs were $59,743 for SAVR, $64,395 for TAVR, and $23,460 for MT.
TAVR IA costs decreased over time to become similar to SAVR costs by 2016. The
TAVR increase was distributed inequitably, with certain patients more likely to receive
TAVR and certain hospitals more likely to provide TAVR. Aggregate costs were higher
for TAVR than SAVR and were significantly more expensive than MT alone. With the

expected expansion of indications, equitable and affordable access to TAVR must be
addressed to minimize disparities and to optimize patient outcomes.
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CHAPTER 1: INTRODUCTION
Therapies for Aortic Valve Disease
Aortic stenosis (AS) and aortic regurgitation (AR) may be treated with one of
three strategies: surgical aortic valve replacement (SAVR), transcatheter aortic valve
replacement (TAVR), or medical therapy (MT). The United States (US) Food and Drug
Administration (FDA) approved TAVR for the treatment of severe AS in inoperable
patients2 in November 2011, high-risk patients 3,4 in October 2012, and intermediaterisk5,6 patients in August 2016. Small numbers of TAVR procedures may performed offlabel for patients with severe AR7 or mixed AS and AR8. However, definitive data are
lacking regarding the actual usage of SAVR, TAVR, and MT for patients hospitalized
with aortic valve disease and the characteristics of the patients and hospitals associated
with each of these therapies.

Rates of SAVR, TAVR, and MT
Prior studies demonstrate an increase in the number of SAVR and TAVR
procedures performed in the US over time. Medicare data for patients over age 65 show
an increase in hospitalizations for SAVR from 24,568 in 1989 to 31,380 in 20119, and
TAVR procedure volumes increased from 4,627 procedures at 198 centers in 2012 to
24,808 procedures at 418 centers in 201510. The relative usage of SAVR and TAVR is
also evolving. In the Society of Thoracic Surgeons database, the absolute number of
TAVR procedures surpassed SAVR procedures in 201611, but the overall rate of SAVR
has remained relatively stable12. Little is known about trends in patients receiving MT.
To address these gaps in knowledge, we sought to characterize temporal trends
in the use of SAVR, TAVR, or MT following admission to US hospitals with a primary or
secondary diagnosis of AS or AR from 2012 through 2016. We hypothesized that the
usage of TAVR has increased particularly in patients with higher surgical risk and at
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urban teaching hospitals, while the number of patients receiving MT and the number of
high-risk patients undergoing SAVR have decreased.

Costs of SAVR, TAVR, and MT
Data also are lacking regarding the relative costs of SAVR, TAVR, and MT for
patients hospitalized with aortic valve disease. Prior studies examining the costs of AS
care have yielded varying results. In general, TAVR has been associated with increased
up-front costs but decreased post-procedural resource utilization in comparison to SAVR
and MT, and follow-up costs have correlated with patients’ procedural risk level. Cost
effectiveness estimates fluctuate widely, particularly as a result of varying costs in
different healthcare systems13. In sum, the actual costs of SAVR, TAVR, and MT remain
poorly understood.
We examined 6-month total inpatient healthcare expenditures for patients with
aortic valve disease admitted from 2012-2016 for valve replacement, heart failure,
unstable angina, non-ST-elevation myocardial infarction, or syncope. We also
performed multivariable and subgroup analyses to investigate the associations of
treatment strategy with costs and inpatient days. In contrast to prior studies, our
inclusive nationwide economic approach captured the largest patient population to date
across diverse health systems and with numerous payment sources. Furthermore,
unlike prior analysis, we sought to compare the costs of SAVR and TAVR to MT. Lastly,
we report 5-year temporal trends in the economics of aortic valve disease care. This
novel information may facilitate future interventions to address disparities in costs and
access to care.
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CHAPTER 2: METHODS
Data
Data were obtained from the Nationwide Readmissions Database (NRD), the
largest, all-payer inpatient care database of the Agency for Healthcare Research and
Quality’s (AHRQ’s) Healthcare Cost and Utilization Project (HCUP) containing an
approximately 20% stratified sample of discharges from all hospitals in 27 US states14.
Data from the NRD and its sister database, the National Inpatient Sample (NIS), have
been used for multiple prior studies evaluating patients who have undergone TAVR15-18.
From the NRD, we obtained de-identified discharge-level data files from 2012 through
2016. Each discharge record includes patient demographics and comorbidities, hospital
characteristics, expected payment source, and discharge status. The NRD also collects
primary and secondary (up to 35) discharge diagnoses and primary and secondary (up
to 15) procedures based on the International Classification of Diseases, Clinical
Modification codes (ICD-9-CM for 2012 through 2015 third quarter, ICD-10-CM for 2015
fourth quarter through 2016). From 2012 through 2016, participation in the HCUP NRD
increased from 18 to 27 states. We linked the NRD with cost-to-charge ratio files from
the Healthcare Cost Report Information System19 to convert total charges to total costs.
We adjusted total costs for each year to 2016 US dollars using the medical care
consumer price index20.

Study Populations
Patient linkage numbers facilitate tracking individual patients across multiple
hospitalizations and between participating states, however, because each annual NRD
data set is independent, individual patients cannot be tracked between years.
Therefore, the study population included all patients who were admitted with aortic valve
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disease and discharged from January 1 through June 30 in each calendar year, allowing
for 6 months of follow-up for every patient.
In the analysis of the rates of SAVR, TAVR, and MT, the index admission (IA)
was defined as the patient's first discharge with a primary or secondary diagnosis of nonrheumatic aortic valve stenosis or regurgitation, which was identified based upon ICD-9CM (424.1) and ICD-10-CM (I35.0, I35.1, I35.2, I35.8, I35.9) codes, plus at least one of
the following procedures or diagnoses: SAVR (ICD-9-CM 35.21, 35.22; ICD-10-CM
02RF07Z, 02RF08Z, 02RF0JZ, 02RF0KZ), TAVR (ICD-9-CM 35.05, 35.06; ICD-10-CM
02RF37H, 02RF37Z, 02RF38H, 02RF38Z, 02RF3JH, 02RF3JZ, 02RF3KH, 02RF3KZ),
congestive heart failure (CHF; ICD-9-CM 428.0, 428.1, 428.20, 428.21, 428.22, 428.23,
428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43; ICD-10-CM I50.1,
I50.20, I50.21, I50.22, I50.23, I50.30, I50.31, I50.32, I50.33, I50,40, I50.41, I50.42,
I50.43), unstable angina (UA; ICD-9-CM 411.1; ICD-10-CM I20.0), non-ST-elevation
myocardial infarction (NSTEMI; ICD-9-CM 410.7 410.70 410.71 410.72; ICD-10-CM
I21.4) or syncope (ICD-9-CM 780.2; ICD-10-CM R55) as any of up to 15 procedures or
any of up to 35 diagnoses.
Treatment strategy was classified as SAVR, TAVR, or MT. ICD-CM codes were
used to identify patients undergoing SAVR and TAVR during the IA or within 180 days of
the IA discharge date. Patients not undergoing SAVR or TAVR within 180 days of IA
discharge were categorized as receiving MT.
In the analysis of costs, inpatient days, and admissions, IA was defined as a
patient's first discharge during which AS/AR (ICD-9-CM 424.1; ICD-10-CM I35.0, I35.1,
I35.2, I35.8, I35.9) was a primary or secondary diagnosis, and SAVR (ICD-9-CM 35.21,
35.22; ICD-10-CM 02RF07Z, 02RF08Z, 02RF0JZ, 02RF0KZ) or TAVR (ICD-9-CM
35.05, 35.06; ICD-10-CM 02RF37H, 02RF37Z, 02RF38H, 02RF38Z, 02RF3JH,
02RF3JZ, 02RF3KH, 02RF3KZ) was performed. For MT, IA was defined as a patient’s
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first discharge with either a primary diagnosis of AS/AR plus a secondary diagnosis of
symptoms or a primary diagnosis of symptoms plus a secondary diagnosis of AS/AR
with no SAVR or TAVR performed during the calendar year. Symptoms included
congestive heart failure (CHF; ICD-9-CM 428.0, 428.1, 428.20, 428.21, 428.22, 428.23,
428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43; ICD-10-CM I50.1,
I50.20, I50.21, I50.22, I50.23, I50.30, I50.31, I50.32, I50.33, I50,40, I50.41, I50.42,
I50.43), unstable angina (UA; ICD-9-CM 411.1; ICD-10-CM I20.0), non-ST-elevation
myocardial infarction (NSTEMI; ICD-9-CM 410.7 410.70 410.71 410.72; ICD-10-CM
I21.4) or syncope (ICD-9-CM 780.2; ICD-10-CM R55). Admissions were excluded from
IA if patients died prior to discharge.
We excluded 2011 data because TAVR was not approved in the United States
until November of that year; only 21 patients in the NRD underwent TAVR in 2011. This
study was exempt from the requirements of the Institutional Review Board at the
University of Nebraska Medical Center because the NRD contains no patient-identifiable
information.

Variables
In the analysis of the rates of SAVR, TAVR, and MT, the primary independent
variable was treatment year. Among explanatory variables, we assessed for patient age
(≤64, 65-74, 75-84, ≥85 years), sex, two health status variables constructed by NRD
(severity of illness and risk of mortality) and the number of comorbid diagnoses reported
during IA (1-10, 11-15, 16-20, 21-35). Age and number of diagnoses were converted to
categorical variables because their relationships with SAVR, TAVR, and MT were highly
non-linear, even with log transformation; all other predictors were presented as
categorical variables by the NRD. Using 3M All Patient Refined Diagnosis Related
Groups21,22, NRD classifies severity of illness into minor (including cases with no
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comorbidity or complications), moderate, major, and extreme loss of function. Similarly,
risk of mortality is categorized into minor, moderate, major, and extreme likelihood of
dying.
We also assessed both for patient insurance status (Medicare, Medicaid, private,
self-pay, no charge/other) and neighborhood median household income as a proxy of
patient socioeconomic status, and county population density as a proxy of urban/rural
location. Quartiles of neighborhood median household income for patient ZIP code were
defined each year (e.g., in 2016, the quartiles were defined as $1-42,999, $43,00053,999, $54,000-70,999, and $71,000 or more). NRD also included county population
density classification constructed by National Center for Health Statistics (less than
249,999, 250,000-999,999, fringe counties of ≥1 million, central counties of ≥1 million
population).
For hospital characteristics, we assessed for ownership (for-profit private; not-forprofit private; government, non-federal), size (small, medium, large per NRD criteria by
region and teaching status23), and status as an urban teaching hospital (urban nonteaching, rural, urban teaching,).
In the analysis of costs, inpatient days, and admissions, the primary independent
variable was treatment strategy (SAVR, TAVR, or MT, as defined in the Methods above).
Explanatory variables were similar to those studied in the first analysis but also included
Charlson comorbidity index24, constructed from ICD-9-CM25 or ICD-10-CM26 codes, as
well as number of inpatient procedures (e.g. echocardiogram, coronary artery bypass
surgery, percutaneous coronary intervention). Age, Charlson comorbidity index, and
number of procedures were converted to categorical variables because their
relationships with 3 outcomes were highly non-linear, even with log transformation; all
other predictors were presented as categorical variables by the NRD. We studied 3
outcomes: total costs, inpatient days, and admissions. We analyzed these outcomes in
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aggregate for all admissions as well as separately for IA only and for 6-month unplanned
readmissions only, using the NRD variable for non-elective admissions. We also
assessed 5-year temporal trends for these outcomes.

Statistical Analysis
Using Pearson Chi-squared tests, we examined systematic differences in the
rates of SAVR, TAVR, and MT between 2012 and 2016, and assessed for systematic
differences between treatment strategy and each explanatory variable.
For multivariate analysis, we employed a multinomial logistic (MNL) model to evaluate
the factors associated with treatment strategy. We tested two MNL models: the first
model used SAVR as the base outcome (which generated two sets of coefficient
estimates, TAVR versus SAVR, and MT versus SAVR), and the second model used MT
as the base outcome (which generated SAVR versus MT and TAVR versus MT).
Coefficients of MNL models were converted to relative risk ratios (RRR)27,28.
We performed three sensitivity analyses to confirm the validity of our methodology. First,
we defined IA using just non-rheumatic AS or AR as any admission diagnosis without
considering other conditions (i.e., SAVR, TAVR, CHF, UA, NSTEMI, or syncope).
Second, we performed the analysis defining IA using only a primary diagnosis of AS or
AR. Third, we repeated the analysis using 3-month and 9-month follow-up periods by
allowing IA from January through September or January through March respectively.
Similarly, we examined differences in each variable according to treatment
strategy using Pearson Chi-squared tests and analysis of variance. To estimate the
effect of treatment strategy on aggregate and IA costs and days, we used a multivariable
generalized linear model with a log link function and a gamma distribution (GLM-LG)29,30.
Given that outcomes were skewed to the right and included outliers, GLM-LG made the
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distribution of outcomes approximately normal and estimated effects without bias. For
unplanned readmission costs and days, we used multivariable two-part models31-33. In
the first part of the two-part models, logistic regression was used to estimate whether
patients had no readmission versus readmission (indicated by zero versus any costs or
inpatient days). In the second part of the model, GLM-LG accounted for total costs and
LOS conditional upon any positive outcome, given that majority of patients had no
readmission31-33. For the aggregate number of admissions and binary outcome of any
unplanned readmission, we used a negative binomial model and a logistic model,
respectively. The coefficients of all estimations were converted into average marginal
effects (AME), allowing us to interpret the effect of treatment strategy on outcomes in
terms of outcome values (i.e., dollars, inpatient days, number of admissions, and
probability of readmission). We performed 2 sensitivity analyses to confirm the validity
of our methodology. First, we defined IA that occurred (i) in January only and (ii)
between January and March, allowing us to track total costs, inpatient days, and
unplanned readmissions for 11 and 9 months, respectively. Second, we estimated total
charges instead of total costs.
All analyses were conducted with Stata MP v.16.0 and accounted for the
discharge weighting in the HCUP NRD survey design in order to produce nationallyrepresentative estimates.
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CHAPTER 3: RESULTS
Trends in SAVR, TAVR, and MT
In the analysis of the rates of SAVR, TAVR, and MT, the sample population
included 366,909 patients with IA discharges for aortic valve disease and one of the
following procedures or diagnoses: SAVR (n = 64,695), TAVR (n = 18,107), CHF (n =
276,955), UA (n = 11,074), NSTEMI (n = 47,749), or syncope (n = 21,858). The average
age was 77.8 years, and 48.7% of the study population was female. Fifty-eight percent
(57.9%) of patients had major or extreme loss of function due to severity of illness, and
53.0% of patients had major or extreme likelihood of dying. Eighty-five percent (85.2%),
3.0%, and 9.6% of patients were covered by Medicare, Medicaid, and private insurance,
respectively (Table 1).
The number of patients hospitalized for aortic valve disease in the first half of
each calendar year increased by 48.1% from 57,516 in 2012 to 85,165 in 2016. Overall,
from 2012 to 2016, January through June, 71,704 (19.9%), 26,173 (6.7%), and 269,032
(73.4%) patients received SAVR, TAVR, and MT, respectively. In 2012, 21.9%, 2.6%,
and 75.5% of patients received each therapy, respectively, however, by 2016, the
proportion undergoing SAVR and MT decreased to 18.5% and 69.0%, while the TAVR
group increased to 12.5% (Table 2).

Therapy Subgroup Analyses
Subgroups stratified by patient, neighborhood, and hospital characteristics
showed similar trends (Figures 1 and 2, P < 0.01 for all). Of note, among the patients
≥75 years of age, the proportion of patients undergoing TAVR increased rapidly,
exceeding the proportion undergoing SAVR in 2016 (Figure 1C, 9.3% for SAVR and
15.1% for TAVR). A similar trend was observed for patients with high severity of illness
(i.e., major and extreme loss of function, Figure 1E, 14.5% for SAVR and 17.3% for
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TAVR). Furthermore, among women (Figure 2B), patients with high predicted mortality
(Figure 2D), and patients hospitalized in a large hospital (Figure 2F) or in a teaching
hospital (Figure 2H), the proportions receiving SAVR and TAVR were similar by 2016.
The same was true for patients at not-for-profit hospitals (Figure 3H), with >20 inpatient
diagnoses (Figure 3B), or living in an urban area (Figure 3D).

Figure 1. Trends in surgical aortic valve replacement (SAVR), transcatheter aortic valve
replacement (TAVR), and medical therapy (MT) from 2012 to 2016: total sample
population and stratified by age and severity of illness.
Notes:
(i) Severity of illness: (D) low (minor or moderate loss of function) vs. (E) high (major or extreme loss of function).
(ii) Percentages were adjusted for Healthcare Cost and Utilization Project Nationwide Readmissions Database (HCUP-NRD)
discharge weights to generate national estimates.

In multivariable analysis using the MNL model, estimates of TAVR versus SAVR
showed that from 2012 to 2016, a patient’s likelihood of receiving TAVR relative to
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SAVR increased by 4.57-fold (RRR 4.57, 95% confidence interval [CI] 4.21-4.97) when
adjusting for patient, hospital, and neighborhood characteristics. Patients ≥85 years of
age (RRR 51.2, 95% CI 46.1-56.7) and those with extreme loss of function (RRR 35.7,
95% CI 29.0-43.8) were most likely to undergo TAVR rather than SAVR. In MNL
multivariable analysis for TAVR versus MT, the likelihood of receiving TAVR relative to
MT continuously increased from 2012 through 2016 (RRR 4.41 versus 2012, 95% CI
4.08-4.77) (Table 3).

Figure 2. Trends in surgical aortic valve replacement (SAVR), transcatheter aortic valve
replacement (TAVR), and medical therapy (MT) from 2012 to 2016: stratified by sex, risk
of mortality, hospital size, and hospital teaching status.
Notes:
(i) Risk of mortality: (C) low (minor or moderate likelihood of dying) vs. (D) high (major or extreme likelihood of dying).
(ii) Non-teaching hospital category in panel (G) includes non-teaching hospitals in urban area and any hospitals in rural area.
(iii) Percentages were adjusted for HCUP-NRD discharge weights to generate national estimates.
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Therapy Sensitivity Analyses
In the first sensitivity analysis, when we expanded the sample population by
defining IA as any admission for AS or AR, regardless of other conditions (i.e., SAVR,
TAVR, CHF, UA, NSTEMI or syncope), we captured 244,432 more patients (n =
611,341). Among the additional patients, 98.4% (n = 240,468) patients received MT,
and numbers of SAVR and TAVR remained virtually unchanged. The estimates for
SAVR vs. TAVR in the multivariate MNL model were similar both in magnitude and
statistical significance as compared to the main analysis (Table 4). In the second
sensitivity analysis, when we restricted the sample population to patients only with a
primary diagnosis of AS or AR (n = 101,834), 19.6% of SAVR, 3.8% of TAVR, and
92.9% of MT patients were eliminated. The MNL models in this sensitivity analysis
remained similar to the main analysis (data not shown). In the third sensitivity analysis,
when we looked at a 3-month window from IA (n = 519,882, SAVR 20.1%, TAVR 6.5%,
MT 73.4%) and a 9-month window from IA (n = 195,427, SAVR 19.3%, TAVR 6.6%, MT
74.1%), the rates of each of the 3 therapies and the multivariate MNL model estimates
(data not shown) remained similar to the 6-month main analysis.
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Figure 3. Trends in surgical aortic valve replacement (SAVR), transcatheter aortic valve
replacement (TAVR), and medical therapy (MT) from 2012 to 2016: stratified by
diagnosis number, hospital location, neighborhood affluence, and hospital not-for-profit
status.
Notes:
(i) Percentages were adjusted for HCUP-NRD discharge weights to generate national estimates.
(ii) Diagnosis number: (A) low (10 or fewer diagnoses) vs. (B) high (more than 20 diagnoses).

Trends in Cost, Inpatient Days, and Admissions
In the analysis of costs, inpatient days, and admissions, the study population
included 190,563 patients with aortic valve disease, of whom 66,564 (35.6%), 21,902
(10.8%), and 102,097 (53.6%) received SAVR, TAVR, and MT alone, respectively.
Patient characteristics are presented in Table 5. Notably, the average age was 76.3
years, 45.0% were female, the average Charlson comorbidity index was 2.1 (SD 0.9),
the average number of inpatient procedures was 2.5 (SD 1.2), 53.6% had major or
extreme loss of function due to severity of illness, and 47.7% had major or extreme
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likelihood of dying. Medicare, Medicaid, and private insurance covered 82.0%, 3.1%,
and 12.5% of patients, respectively.
The aggregate average 6-month inpatient cost including all admissions was
$40,79041,730, corresponding to $59,743 for SAVR, $64,395 for TAVR, and $23,460
for MT. However, following IA, the average 6-month cost of readmissions only was
$5505 for SAVR, $7455 for TAVR, and $10,013 for MT (Figure 4; p<0.01 for all).
Among the total study population, the mean number of inpatient days was 10.611.5
days for all admissions across 6 months. IA was longer for SAVR (10.0 days) than for
TAVR (7.0 day) or MT (5.3 days). However, the average number of unplanned
readmission inpatient days was 2.0 for SAVR, 3.0 for TAVR, and 4.3 for MT (Figure 5;
p<0.01 for all).
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Figure 4. Total costs during all admissions, index admission only, and readmissions
only (n=190,563).
Notes:
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).
(ii) Lower, middle, and upper hinges of box graph represent 25th percentile, 50th percentile (median), and 75th percentile of costs.
Lower and upper whiskers represent Tukey’s interquartile ranges34.
(iii) •: mean, ♦: 5th percentile, ▲: 95th percentile
(iv) All values adjusted for HCUP-NRD discharge weights to generate nationally-representative estimates.
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Figure 5. Inpatient days during all admissions, index admission only, and readmissions
only (n=190,563).
Notes:
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).
(ii) Lower, middle, and upper hinges of box graph represent 25th percentile, 50th percentile (median), and 75th percentile of days.
Lower and upper whiskers represent Tukey’s interquartile ranges34.
(iii) •: mean, ♦: 5th percentile, ▲: 95th percentile
(iv) All values adjusted for HCUP-NRD discharge weights to generate nationally-representative estimates.

The average number of total admissions over 6 months was 1.61.0,
corresponding to 1.3 for SAVR, 1.5 for TAVR, and 1.7 for MT. The probability of any
readmission followed the same trend: 0.23 for SAVR, 0.32 for TAVR, and 0.43 for MT
(p<0.01 for all).
In multivariable analysis (Table 6), compared to patients receiving SAVR, total
costs during IA were higher among patients receiving TAVR by $4246 (AME; 95%
confidence interval [CI] $3679, $4813) but lower among patients receiving MT by
$25,556 (AME; 95% CI -$25,886, -$25,226). However, compared to patients receiving
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SAVR, total costs during all unplanned readmissions were higher among patients
receiving TAVR by $4044 (AME; 95% CI $3643, $4444) and by $4,164 among patients
receiving MT (AME; 95% CI $3888, $4440).
In multivariable analysis for number of inpatient days (Table 7), compared to
patients receiving SAVR, IA was shorter by 3.2 days among patients receiving TAVR
(AME; 95% CI -3.3, -3.1) and by 2.7 days among patients receiving MT (AME; 95% CI 2.8, -2.6). However, compared to patients receiving SAVR, 6-month unplanned
readmission inpatient days were higher by 1.5 days among patients receiving TAVR
(AME; 95% CI 1.4, 1.7) and by 1.6 days among patients receiving MT (AME; 95% CI
1.4, 1.7).
In multivariable analysis for number of admissions and any unplanned
readmission (Table 8), compared to patients receiving SAVR, the probability of
readmission was higher by 0.18 (AME; 95% CI 0.16, 0.19) among patients receiving
TAVR and by 0.07 (AME; 95% CI 0.06, 0.07) among patients receiving MT.
The average cost of TAVR IA was higher than SAVR IA from 2012-2016,
however, costs of TAVR IA has decreased rapidly after 2013, and the IA cost difference
between TAVR and SAVR was not statistically significant in 2016 ($52,487 for TAVR vs.
$52,204 for SAVR, p=0.66; Figure 6). Inpatient days and readmission rates for TAVR
decreased over time as well. While average IA inpatient days for TAVR (9.2 days) and
SAVR (10.3 days) were similar in 2013, by 2016, IA was much shorter for TAVR (5.4
days) than SAVR (9.5 days, p<0.01).
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Figure 6. Trends of total costs, inpatient days, and number of admissions from 2012 to
2016 (n=190,563).
Notes:
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).
(ii) Sum (both IA and RA), IA (index admission), RA (readmissions).
(ii) Mean was adjusted for HCUP-NRD discharge weights to generate nationally representative estimates.

Cost Subgroup Analyses
Most results were similar in subgroup analyses. However, during IA only, in
comparison to the total study population, the excess cost for TAVR vs. SAVR was less
among patients age ≤74 (AME $1334; 95% CI $609, $2528), small and medium size
hospitals (AME $3755; 95% CI $2548, $4942), non-teaching hospitals and hospitals in
non-metropolitan areas (AME $2940; 95% CI $1674, $4206), and poor neighborhoods
(AME $3673; 95% CI $2877, $4470). Conversely, the excess cost of TAVR vs. SAVR IA
was most pronounced (AME $13,485; 95% CI $12,427, $14,543) among patients with
minor or moderate loss of function.
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For inpatient days, TAVR resulted in shorter IA than SAVR (AME -3.2 days, 95%
CI, -3.3, -3.1) among the total study population, however this effect was less dramatic
among patients with minor or moderate loss of function (AME -0.7, 95% CI -0.9, -0.4).
During readmissions, TAVR was actually associated with more inpatient days than
SAVR (AME 1.5, 95% CI, 1.4, 1.7) among the total study population, but only a very
modest effect was observed in patients with extreme loss of function (AME 0.2, 95% CI,
0.2, 0.2).

Cost Sensitivity Analyses
In the first sensitivity analyses, when we defined IA during January only with 11
months of follow-up or during January through March with 9 months of follow-up, most
results were similar to the primary analysis (Table 9). In the second sensitivity analysis,
the average aggregate total charge was $155,949±177,656 (Figure 7). Analyses for total
charges showed patterns similar to total costs (Table 10).
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Figure 7. Total charges during all admissions, index admission only, and readmissions
only (n=190,563).
Notes:
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).
(ii) Lower, middle, and upper hinges of box graph represent 25th percentile, 50th percentile (median), and 75th percentile of charges.
Lower and upper whiskers represent Tukey’s interquartile ranges34.
(iii) •: mean, ♦: 5th percentile, ▲: 95th percentile
(iv) All values adjusted for HCUP-NRD discharge weights to generate nationally-representative estimates.

21

Table 1. Patient characteristics and neighborhood information among total sample
population and stratified by treatment strategy (No. (%)).
Total sample
(n = 366909)

SAVR
(n = 71704)

TAVR
(n = 26173)

MT
(n = 269032)

p-value

Age category
p < 0.01
64 or less
47077 (13.2)
20399 (43.9)
1062 (2.1)
25616 (54.0)
65-74
71762 (19.6)
24171 (33.9)
3813 (5.0)
43778 (61.1)
75-84
117206 (32.0)
22780 (19.7)
10333 (8.3)
84093 (72.0)
85 or above
130864 (35.2)
4354 (3.4)
10965 (8.0) 115545 (88.6)
Women
177681 (48.7)
24405 (14.1)
12145 (6.4) 141131 (79.5)
p < 0.01
Severity of illness
p < 0.01
Minor loss of function
17761 (4.9)
4918 (27.9)
152 (0.8)
12691 (71.3)
Moderate loss of function
134278 (37.2)
32093 (24.0)
3775 (2.7)
98410 (73.3)
Major loss of function
164340 (44.5)
27935 (17.3)
10948 (6.4) 125457 (76.3)
Extreme loss of function
50530 (13.4)
6758 (14.1) 11298 (21.5)
32474 (64.4)
Risk of mortality
p < 0.01
Minor likelihood of dying
21914 (6.1)
11029 (51.0)
1363 (5.6)
9522 (43.4)
Moderate likelihood of dying
148353 (40.8)
32363 (22.1)
12622 (7.9) 103368 (70.0)
Major likelihood of dying
152437 (41.3)
21673 (14.4)
10519 (6.6) 120245 (79.0)
Extreme likelihood of dying
44205 (11.8)
6639 (15.8)
1669 (3.6)
35897 (80.6)
Number of diagnoses
p < 0.01
1-10
48545 (13.8)
18923 (39.4)
3011 (5.5)
26611 (55.1)
11-15
111841 (30.6)
24060 (21.3)
8277 (6.8)
79504 (71.9)
16-20
115774 (31.3)
16990 (14.9)
9137 (7.5)
89647 (77.6)
21-35
90749 (24.3)
11731 (13.6)
5748 (6.4)
73270 (80.1)
Insurance status
p < 0.01
Medicare
311844 (85.2)
49467 (16.1)
24362 (7.4) 238013 (76.5)
Medicaid
11843 (3.0)
3319 (28.6)
244 (2.0)
8280 (69.4)
Private
35300 (9.6)
16735 (48.8)
1221 (3.2)
17346 (48.0)
Self-pay
2733 (0.8)
824 (30.9)
87 (2.7)
1822 (66.4)
No charge/other
5188 (1.4)
1359 (27.4)
259 (5.4)
3570 (67.3)
Neighborhood median household income
p < 0.01
Bottom quartile
86423 (24.9)
15393 (17.9)
5117 (5.6)
65910 (76.5)
Second quartile
91441 (26.1)
18112 (20.3)
6224 (6.6)
67106 (73.1)
Third quartile
94957 (25.5)
19187 (20.8)
7075 (7.2)
68697 (72.0)
Top quartile
94087 (23.5)
19012 (20.6)
7757 (7.6)
67319 (71.8)
Patient urban-rural classification
p < 0.01
Counties < 249,999
88376 (28.6)
18706 (21.2)
5962 (6.5)
63709 (72.3)
Counties 250,000-999,999
78109 (20.6)
16786 (22.0)
5625 (7.0)
55698 (71.0)
Fringe counties, ≥1 million
97908 (27.4)
18372 (19.2)
7697 (7.1)
71839 (73.7)
Central counties, ≥1 million
102516 (23.4)
17841 (17.4)
6889 (6.4)
77786 (76.2)
Notes:
(i) Percentages adjusted for HCUP-NRD discharge weights to generate national estimates, accounting for slight deviation from the
percentage calculated from the raw numbers.
(ii) Percentages in total sample are column percentages. Percentages in subsample population (SAVR, TAVR, and MT) are row
percentages.
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Table 2. Treatment strategy, year, and hospital characteristics among total sample
population and stratified by treatment strategy (No. (%)).
Total sample

SAVR

TAVR

MT

(n = 366909)

(n = 71704)

(n = 26173)

(n = 269032)

Treatment strategy

p-value
p < 0.01

SAVR

71704 (19.9)

71704 (100)

0 (0.0)

0 (0.0)

-

TAVR

26173 (6.7)

0 (0)

26173 (100)

0 (0.0)

-

269032 (73.4)

0 (0)

0 (0)

269032 (100)

-

MT
Year

p < 0.01

2012

57516 (18.2)

12290 (21.9)

1557 (2.6)

43669 (75.5)

-

2013

65880 (19.4)

13608 (20.7)

3040 (4.5)

49232 (74.8)

-

2014

69121 (19.7)

14012 (20.5)

4045 (5.6)

51064 (73.9)

-

2015

89227 (21.8)

16247 (18.4)

6904 (7.6)

66076 (74.0)

-

2016

85165 (20.9)

15547 (18.5)

10627 (12.5)

58991 (69.0)

Hospital ownership
Private, investor-owned

p < 0.01

43434 (10.7)

7806 (17.9)

1349 (2.9)

34279 (79.2)

-

283908 (79.2)

57237 (20.6)

21957 (7.2)

204714 (72.2)

-

39567 (10.1)

6661 (16.8)

2867 (6.9)

30039 (76.3)

-

Small

36119 (11.0)

3892 (11.4)

768 (1.9)

31459 (86.7)

-

Medium

89810 (23.1)

14101 (16.1)

4004 (4.1)

71705 (79.8)

-

240980 (65.9)

53711 (22.7)

21401 (8.5)

165868 (68.8)

Private, not-for-profit
Government, non-federal
Hospital size

Large

p < 0.01

Hospital teaching status
Urban, non-teaching
Rural

p < 0.01

109350 (27.6)

15686 (14.9)

2208 (2.0)

91456 (83.1)

-

22285 (8.3)

1215 (5.7)

237 (1.0)

20833 (93.3)

-

Urban, teaching
235274 (64.1) 54803 (24.0)
23728 (9.5) 156743 (66.5)
Notes:
(i) Percentages adjusted for HCUP-NRD discharge weights to generate national estimates, accounting for slight deviation from the
percentage calculated from the raw numbers.
(ii) Percentages in total sample are column percentages. Percentages in subsample population (SAVR, TAVR, and MT) are row
percentages.

23
Table 3. Association of year, patient characteristics, and hospital characteristics with
treatment strategy (n = 366,909).
TAVR vs. SAVR
RRR (95% CI)
Year
2012
1 [reference]
2013
1.79 (1.64-1.96)
2014
2.13 (1.95-2.33)
2015
2.84 (2.61-3.09)
2016
4.57 (4.21-4.97)
Age category
64 or less
1 [reference]
65-74
2.64 (2.39-2.92)
75-84
8.51 (7.72-9.37)
85 or above
51.2 (46.1-56.7)
Women
1.29 (1.24-1.34)
Severity of illness
Minor loss of function
1 [reference]
Moderate loss of function
3.16 (2.61-3.84)
Major loss of function
17.8 (14.6-21.7)
Extreme loss of function
35.7 (29.0-43.8)
Risk of mortality
Minor likelihood of dying
1 [reference]
Moderate likelihood of dying
0.55 (0.51-0.60)
Major likelihood of dying
0.16 (0.14-0.17)
Extreme likelihood of dying
0.01 (0.01-0.01)
Number of diagnoses
1-10
1 [reference]
11-15
1.47 (1.38-1.57)
16-20
1.95 (1.82-2.08)
21-35
1.58 (1.46-1.70)
Insurance status
Medicare
1 [reference]
Medicaid
0.57 (0.47-0.68)
Private
0.48 (0.44-0.53)
Self-pay
0.65 (0.50-0.85)
No charge/other
0.72 (0.60-0.85)
Neighborhood median household income
Bottom quartile
1 [reference]
Second quartile
0.94 (0.89-1.00)
Third quartile
0.93 (0.88-0.99)
Top quartile
0.90 (0.84-0.95)
Patient urban-rural classification
Counties <249,999
1 [reference]
Counties 250,000-999,999
0.93 (0.88-0.99)
Fringe counties, ≥1 million
1.09 (1.02-1.16)
Central counties, ≥1 million
0.93 (0.88-0.99)
Hospital ownership
Private, investor-owned
1 [reference]
Private, not-for-profit
1.33 (1.24-1.43)
Government, non-federal
1.77 (1.61-1.94)
Hospital size
Small
1 [reference]
Medium
1.62 (1.45-1.80)
Large
2.63 (2.38-2.91)

SAVR vs. MT
RRR (95% CI)

TAVR vs. MT
RRR (95% CI)

1 [reference]
1.00 (0.96-1.04)
0.96 (0.92-0.99)
0.90 (0.87-0.94)
0.96 (0.93-1.00)

1 [reference]
1.78 (1.64-1.94)
2.04 (1.87-2.21)
2.56 (2.37-2.77)
4.41 (4.08-4.77)

1 [reference]
1.07 (1.03-1.11)
0.62 (0.59-0.64)
0.09 (0.09-0.10)
0.62 (0.61-0.63)

1 [reference]
2.84 (2.57-3.13)
5.25 (4.77-5.77)
4.81 (4.37-5.30)
0.80 (0.77-0.83)

1 [reference]
1.89 (1.79-1.99)
2.25 (2.12-2.39)
2.58 (2.38-2.79)

1 [reference]
5.97 (4.94-7.23)
40.2 (33.3-48.8)
92.0 (75.3-112)

1 [reference]
0.56 (0.53-0.58)
0.41 (0.39-0.43)
0.44 (0.41-0.48)

1 [reference]
0.31 (0.28-0.33)
0.06 (0.06-0.07)
<0.01 (0.00-0.00)

1 [reference]
0.44 (0.43-0.46)
0.27 (0.26-0.28)
0.22 (0.21-0.23)

1 [reference]
0.65 (0.61-0.69)
0.53 (0.49-0.56)
0.34 (0.32-0.37)

1 [reference]
0.86 (0.81-0.91)
1.87 (1.80-1.94)
0.87 (0.78-0.97)
1.02 (0.94-1.12)

1 [reference]
0.49 (0.41-0.58)
0.91 (0.83-0.99)
0.56 (0.44-0.73)
0.73 (0.62-0.87)

1 [reference]
1.34 (1.30-1.38)
1.43 (1.38-1.47)
1.61 (1.56-1.67)

1 [reference]
1.26 (1.19-1.33)
1.32 (1.26-1.40)
1.44 (1.37-1.53)

1 [reference]
0.72 (0.69-0.74)
0.63 (0.61-0.65)
0.51 (0.50-0.53)

1 [reference]
0.67 (0.63-0.71)
0.68 (0.65-0.72)
0.48 (0.45-0.51)

1 [reference]
0.87 (0.83-0.90)
0.54 (0.52-0.57)

1 [reference]
1.15 (1.08-1.23)
0.96 (0.88-1.04)

1 [reference]
1.57 (1.49-1.65)
2.88 (2.75-3.02)

1 [reference]
2.54 (2.30-2.79)
7.58 (6.91-8.31)
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Hospital teaching status
Urban, non-teaching
Rural
Urban, teaching

1 [reference]
1.34 (1.13-1.57)
2.85 (2.69-3.02)

1 [reference]
0.28 (0.26-0.30)
2.14 (2.09-2.20)

1 [reference]
0.37 (0.32-0.43)
6.11 (5.78-6.45)
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Table 4. Sensitivity analysis: association of year, patient characteristics, and hospital
characteristics with treatment strategy in patients admitted with any diagnosis of AS or
AR (n = 611,341).
TAVR vs. SAVR SAVR vs. MT
RRR (95% CI) RRR (95% CI)
Year
2012
1 [reference]
2013
1.77 (1.63-1.93)
2014
2.13 (1.97-2.32)
2015
2.86 (2.65-3.10)
2016
4.85 (4.49-5.24)
Age category
64 or less
1 [reference]
65-74
2.85 (2.59-3.14)
75-84
9.53 (8.69-10.4)
85 or above
55.2 (49.9-60.9)
Women
1.31 (1.26-1.36)
Severity of illness
Minor loss of function
1 [reference]
Moderate loss of function
3.82 (3.24-4.50)
Major loss of function
21.6 (18.2-25.5)
Extreme loss of function
40.8 (34.1-48.9)
Risk of mortality
Minor likelihood of dying
1 [reference]
Moderate likelihood of dying 0.48 (0.45-0.52)
Major likelihood of dying
0.13 (0.12-0.14)
Extreme likelihood of dying 0.01 (0.01-0.01)
Number of diagnoses
1-10
1 [reference]
11-15
1.35 (1.28-1.43)
16-20
1.64 (1.55-1.75)
21-35
1.26 (1.17-1.35)
Insurance status
Medicare
1 [reference]
Medicaid
0.51 (0.43-0.61)
Private
0.46 (0.43-0.50)
Self-pay
0.57 (0.44-0.74)
No charge/other
0.70 (0.59-0.83)
Neighborhood median household income
Bottom quartile
1 [reference]
Second quartile
0.97 (0.92-1.02)
Third quartile
0.96 (0.91-1.01)
Top quartile
0.96 (0.90-1.01)
Patient urban-rural classification
Counties <249,999
1 [reference]
Counties 250,000-999,999 0.92 (0.87-0.97)
Fringe counties, ≥1 million 1.11 (1.05-1.17)
Central counties, ≥1 million 0.92 (0.87-0.97)
Hospital ownership
Private, investor-owned
1 [reference]
Private, not-for-profit
1.38 (1.29-1.48)
Government, non-federal
1.76 (1.61-1.91)
Hospital size

TAVR vs. MT
RRR (95% CI)

1 [reference]
0.97 (0.94-1.01)
0.94 (0.91-0.97)
0.87 (0.84-0.90)
0.81 (0.78-0.84)

1 [reference]
1.72 (1.59-1.86)
2.00 (1.86-2.17)
2.49 (2.31-2.68)
3.94 (3.66-4.23)

1 [reference]
1.04 (1.01-1.08)
0.63 (0.61-0.65)
0.11 (0.11-0.12)
0.60 (0.58-0.61)

1 [reference]
2.98 (2.71-3.27)
5.98 (5.46-6.54)
6.15 (5.61-6.74)
0.78 (0.76-0.81)

1 [reference]
1 [reference]
2.07 (1.99-2.15) 7.90 (6.72-9.29)
2.38 (2.27-2.49) 51.3 (43.5-60.5)
2.58 (2.41-2.76)
105 (89-125)
1 [reference]
1 [reference]
1.24 (1.20-1.28) 0.60 (0.56-0.64)
1.12 (1.07-1.16) 0.14 (0.13-0.15)
1.27 (1.19-1.36) 0.01 (0.01-0.01)
1 [reference]
1 [reference]
0.61 (0.59-0.63) 0.82 (0.78-0.87)
0.42 (0.41-0.44) 0.70 (0.66-0.74)
0.36 (0.35-0.37) 0.45 (0.42-0.48)
1 [reference]
0.87 (0.83-0.92)
1.67 (1.62-1.72)
0.94 (0.86-1.03)
1.01 (0.94-1.09)

1 [reference]
0.45 (0.38-0.53)
0.78 (0.72-0.84)
0.54 (0.42-0.70)
0.71 (0.61-0.83)

1 [reference]
1 [reference]
1.24 (1.21-1.28) 1.20 (1.14-1.26)
1.29 (1.25-1.33) 1.23 (1.17-1.29)
1.37 (1.33-1.42) 1.31 (1.25-1.38)
1 [reference]
1 [reference]
0.71 (0.69-0.73) 0.65 (0.62-0.68)
0.64 (0.62-0.66) 0.70 (0.67-0.74)
0.52 (0.51-0.54) 0.48 (0.46-0.51)
1 [reference]
1 [reference]
0.85 (0.82-0.87) 1.17 (1.09-1.24)
0.56 (0.54-0.59) 0.99 (0.91-1.07)
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Small
Medium
Large
Hospital teaching status
Urban, non-teaching
Rural
Urban, teaching

1 [reference]
1 [reference]
1 [reference]
1.65 (1.49-1.83) 1.62 (1.54-1.69) 2.67 (2.43-2.93)
2.74 (2.49-3.01) 2.89 (2.77-3.02) 7.91 (7.25-8.63)
1 [reference]
1 [reference]
1 [reference]
1.32 (1.13-1.54) 0.30 (0.28-0.32) 0.39 (0.34-0.45)
2.92 (2.76-3.09) 2.05 (2.00-2.10) 5.99 (5.68-6.30)
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Table 5. Patient, hospital, and neighborhood characteristics among total study
population and stratified by treatment strategy (No. (%)).
Total study
population
(n = 190,563)
Age category
64
29320 (15.8)
65-74
41428 (21.7)
75-84
60847 (31.9)
85
58968 (30.6)
Women
85231 (45.0)
Charlson comorbidity index
0-1
59104 (31.4)
2-3
74157 (39.0)
4-5
43635 (22.7)
6
13667 (6.9)
Number of inpatient procedures
0
48881 (25.6)
1-2
49863 (26.2)
3-4
38493 (20.2)
53326 (28.0)
5
Severity of illness
Minor loss of function
11720 (6.2)
Moderate loss of function
75541 (40.2)
Major loss of function
78008 (40.8)
Extreme loss of function
25294 (12.8)
Risk of mortality
Minor likelihood of dying
16450 (8.8)
Moderate likelihood of dying
82482 (43.5)
Major likelihood of dying
75857 (39.4)
Extreme likelihood of dying
15774 (8.3)
Insurance status
Medicare
156247 (82.0)
Medicaid
6349 (3.1)
Private
23535 (12.5)
Self-pay
1602 (0.9)
No charge/other
2829 (1.5)
Neighborhood median household income
Bottom quartile
43864 (24.2)
Second quartile
47721 (26.2)
Third quartile
49682 (25.8)
Top quartile
49296 (23.8)
Patient urban-rural classification
Counties <249,999
46872 (29.0)
Counties 250,000-999,999
41545 (21.2)
Fringe counties, ≥1 million
51267 (27.5)
Central counties, ≥1 million
50879 (22.3)
Hospital ownership
Private, investor-owned
22298 (10.6)
Private, not-for-profit
148494 (79.8)

SAVR

TAVR

MT

(n = 66,564;
35.6%)

(n = 21,902;
10.8%)

(n = 102,097;
53.6%)

19084 (29.2)
22585 (33.5)
21024 (31.5)
3871 (5.8)
22444 (34.1)

863 (4.0)
3157 (14.3)
8669 (39.7)
9213 (41.9)
10042 (46.0)

9373 (9.3)
15686 (15.3)
31154 (30.5)
45884 (44.8)
52745 (52.0)

35263 (53.4)
22386 (33.6)
7234 (10.7)
1681 (2.4)

5452 (24.9)
9296 (42.5)
5500 (25.1)
1654 (7.5)

18389 (18.2)
42475 (41.9)
30901 (30.2)
10332 (9.7)

0 (0)
10402 (15.8)
19959 (30.0)
36203 (54.2)

0 (0.0)
8743 (39.4)
6293 (29.0)
6866 (31.5)

48881 (48.9)
30718 (29.7)
12241 (11.6)
10257 (9.8)

4295 (6.5)
29646 (44.6)
26749 (39.9)
5874 (8.9)

109 (0.5)
2024 (9.4)
6630 (30.5)
13139 (59.6)

7316 (7.2)
43871 (43.4)
44629 (43.4)
6281 (6.0)

10225 (15.6)
30019 (45.2)
20619 (30.5)
5701 (8.7)

1220 (5.5)
10001 (45.5)
9166 (42.1)
1515 (6.9)

5005 (5.0)
42462 (42.0)
46072 (44.8)
8558 (8.3)

45571 (68.4)
2974 (4.2)
15963 (24.2)
755 (1.2)
1301 (2.0)

20274 (92.5)
202 (0.9)
1080 (4.9)
95 (0.4)
251 (1.3)

90400 (88.9)
3173 (2.9)
6494 (6.2)
753 (0.7)
1277 (1.2)

14080 (22.0)
16770 (26.6)
17828 (26.7)
17886 (24.7)

4213 (20.5)
5212 (25.5)
5889 (27.0)
6588 (27.0)

25568 (26.3)
25739 (26.2)
25967 (24.9)
24824 (22.6)

17346 (30.4)
15607 (22.8)
17135 (26.5)
16476 (20.3)

5012 (27.5)
4707 (21.4)
6442 (29.1)
5741 (22.0)

24514 (28.4)
21231 (20.0)
27690 (27.8)
28662 (23.7)

7398 (9.9)
53278 (82.0)

1191 (5.0)
18509 (85.7)

13709 (12.2)
76707 (77.1)

P-value

< 0.01
< 0.01
< 0.01
< 0.01

< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
-

28
Government, non-federal
19771 (9.6)
5888 (8.1)
2202 (9.3)
11681 (10.7)
Hospital size
< 0.01
Small
16690 (9.8)
3802 (6.6)
725 (3.5)
12163 (13.3)
Medium
44326 (22.0)
13304 (19.0)
3528 (14.9)
27494 (25.4)
Large
129547 (68.2)
49458 (74.4)
17649 (81.7)
62440 (61.3)
Hospital teaching status
< 0.01
Urban, non-teaching
51878 (25.5)
14822 (21.0)
1951 (8.6)
35105 (31.9)
Non-metropolitan
9409 (6.8)
1044 (2.2)
178 (1.1)
8187 (10.9)
Urban, teaching
129276 (67.7)
50698 (76.8)
19773 (90.2)
58805 (57.2)
Year
< 0.01
2012
29235 (17.9)
11323 (19.8)
1239 (6.8)
16673 (18.8)
2013
33685 (19.2)
12551 (20.1)
2466 (12.8)
18668 (19.9)
2014
35400 (19.4)
13012 (20.2)
3177 (15.3)
19211 (19.7)
2015
44847 (21.1)
15114 (20.2)
5730 (24.5)
24003 (21.0)
2016
47396 (22.4)
14564 (19.7)
9290 (40.6)
23542 (20.6)
Notes:
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).
(ii) Percentages were adjusted for HCUP-NRD discharge weights to generate national estimates, which accounts for their slight
deviation from the percentage calculated from the raw numbers.
(iii) P-values were derived by Pearson Chi-squared tests and analysis of variance.
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Table 6. Association of treatment strategy with total cost: total cost during all
admissions, index admission only, and readmissions only (n = 190,563).
All admissions
AME in $ (95% CI)

Index admission only
AME in $ (95% CI)

Readmissions only
AME in $ (95% CI)

Treatment strategy
SAVR
TAVR
6559 (5750, 7369)
4246 (3679, 4813)
4044 (3643, 4444)
MT
-22825 (-23360, -22291)
-25556 (-25886, -25226)
4164 (3888, 4440)
Age category
64
65-74
-6058 (-6929, -5187)
-1642 (-2171, -1114)
-3359 (-3905, -2812)
75-84
-8192 (-9077, -7307)
-2660 (-3196, -2125)
-4023 (-4562, -3483)
85
-11934 (-12854, -11015)
-4440 (-5008, -3873)
-5113 (-5655, -4571)
Women
305 (-52, 662)
-80 (-305, 144)
274 (88, 460)
Charlson comorbidity index
0-1
2-3
5435 (4986, 5885)
1670 (1381, 1959)
2829 (2609, 3049)
4-5
9316 (8740, 9892)
3688 (3330, 4046)
4327 (4046, 4609)
9774 (8928, 10619)
6608 (6073, 7142)
3926 (3519, 4334)
6
Number of inpatient procedures
0
1-2
16398 (16015, 16780)
9008 (8800, 9217)
5271 (5056, 5487)
3-4
22607 (22129, 23085)
16623 (16384, 16863)
4838 (4537, 5140)
5
30738 (30180, 31295)
30058 (29720, 30397)
2697 (2333, 3061)
Severity of illness
Minor loss of function
Moderate loss of function
5784 (5116, 6452)
1114 (619, 1609)
2672 (2296, 3048)
Major loss of function
9645 (8891, 10400)
5006 (4449, 5564)
3382 (2965, 3800)
Extreme loss of function
8018 (7025, 9011)
10404 (9596, 11212) -3632 (-4080, -3185)
Risk of mortality
Minor likelihood of dying
Moderate likelihood of dying
5264 (4733, 5796)
823 (466, 1181)
3098 (2786, 3410)
Major likelihood of dying
7451 (6770, 8132)
3599 (3145, 4054)
3206 (2830, 3581)
Extreme likelihood of dying
11519 (10334, 12704)
11147 (10269, 12025)
-185 (-709, 340)
Insurance status
Medicare
Medicaid
4143 (2723, 5563)
2999 (2139, 3860)
942 (221, 1663)
Private
-6078 (-6697, -5458)
-521 (-968, -73) -3629 (-3928, -3330)
Self-pay
-9276 (-11205, -7346)
-934 (-2812, 945) -5246 (-5855, -4638)
No charge/other
-6225 (-7638, -4812)
1114 (-151, 2379) -4852 (-5355, -4349)
Neighborhood median household income
Bottom quartile
Second quartile
963 (472, 1454)
1253 (948, 1557)
100 (-158, 359)
Third quartile
2015 (1490, 2540)
2719 (2394, 3044)
74 (-192, 339)
Top quartile
4548 (3990, 5107)
5162 (4810, 5514)
495 (202, 788)
Patient urban-rural classification
Counties <249,999
Counties 250,000-999,999
-386 (-896, 124)
-1013 (-1351, -674)
403 (151, 654)
Fringe counties, ≥1 million
2524 (1938, 3110)
-298 (-663, 68)
2010 (1721, 2300)
Central counties, ≥1 million
7322 (6745, 7900)
4080 (3713, 4447)
2875 (2585, 3166)
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Hospital ownership
Private, investor-owned
Private, not-for-profit
5526 (5048, 6005)
4179 (3886, 4471)
1488 (1238, 1739)
Government, non-federal
12819 (11976, 13662)
6916 (6452, 7379)
4489 (4059, 4919)
Hospital size
Small
Medium
1090 (411, 1769)
-1367 (-1825, -909)
1120 (826, 1414)
Large
5410 (4786, 6033)
-327 (-754, 99)
3324 (3045, 3603)
Hospital teaching status
Urban, non-teaching
Non-metropolitan
-69 (-903, 765)
658 (84, 1231)
358 (-19, 736)
Urban, teaching
3302 (2896, 3707)
8 (-249, 265)
2008 (1805, 2211)
Year
2012
2013
-1233 (-1904, -563)
-403 (-810, 4)
-779 (-1129, -429)
2014
-2953 (-3584, -2321)
-1620 (-2001, -1239)
-1182 (-1531, -833)
2015
-3666 (-4277, -3056)
-1867 (-2244, -1491) -1458 (-1794, -1123)
2016
-4029 (-4638, -3420)
-1549 (-1929, -1168) -1804 (-2139, -1470)
Notes:
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).
(ii) Average marginal effects (AME; $) and 95% confidence interval (CI) were adjusted for HCUP-NRD discharge weights to
generate nationally representative estimates.
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Table 7. Association of treatment strategy with inpatient days: inpatient days during all
admissions, index admission only, and readmissions only (n = 190,563).
All admissions
AME in days (95% CI)
Treatment strategy
SAVR
TAVR
MT
Age category
64
65-74
75-84
85
Women
Charlson comorbidity index
0-1
2-3
4-5
6
Number of inpatient procedures
0
1-2
3-4
5
Severity of illness
Minor loss of function
Moderate loss of function
Major loss of function
Extreme loss of function
Risk of mortality
Minor likelihood of dying
Moderate likelihood of dying
Major likelihood of dying
Extreme likelihood of dying
Insurance status
Medicare
Medicaid
Private
Self-pay
No charge/other
Neighborhood median household income
Bottom quartile
Second quartile
Third quartile
Top quartile
Patient urban-rural classification
Counties <249,999
Counties 250,000-999,999
Fringe counties, ≥1 million
Central counties, ≥ 1 million

Index admission only
AME in days (95% CI)

Readmissions only
AME in days (95% CI)

-2.6 (-2.8, -2.4)
-1.7 (-1.8, -1.5)

-3.2 (-3.3, -3.1)
-2.7 (-2.8, -2.6)

1.5 (1.4, 1.7)
1.6 (1.4, 1.7)

-1.8 (-2.1, -1.6)
-1.6 (-1.9, -1.4)
-1.9 (-2.1, -1.6)
0.8 (0.7, 0.9)

-0.5 (-0.6, -0.4)
-0.2 (-0.3, -0.1)
0.1 (-0.1, 0.2)
0.5 (0.5, 0.6)

-1.2 (-1.4, -1.0)
-1.2 (-1.5, -1.0)
-1.6 (-1.8, -1.4)
0.3 (0.2, 0.3)

2.1 (2.0, 2.3)
3.5 (3.3, 3.6)
3.5 (3.3, 3.8)

0.8 (0.7, 0.9)
1.6 (1.5, 1.7)
2.3 (2.1, 2.4)

1.2 (1.1, 1.3)
1.8 (1.7, 1.9)
1.5 (1.4, 1.7)

3.1 (3.0, 3.3)
3.2 (3.1, 3.4)
4.6 (4.4, 4.8)

1.1 (1.0, 1.1)
1.9 (1.9, 2.0)
5.1 (5.0, 5.2)

1.9 (1.8, 1.9)
1.2 (1.0, 1.3)
0.0 (-0.2, 0.1)

2.3 (2.1, 2.5)
3.3 (3.1, 3.6)
0.7 (0.4, 1.0)

0.8 (0.7, 0.9)
1.8 (1.7, 1.9)
2.0 (1.8, 2.2)

1.3 (1.2, 1.5)
1.6 (1.5, 1.8)
-1.3 (-1.4, -1.1)

2.3 (2.2, 2.5)
3.7 (3.5, 3.9)
6.9 (6.5, 7.3)

0.8 (0.7, 0.9)
2.0 (1.9, 2.1)
4.7 (4.5, 4.9)

1.3 (1.2, 1.4)
1.3 (1.1, 1.4)
-0.2 (-0.4, 0.0)

1.6 (1.2, 2.1)
-2.4 (-2.6, -2.2)
-1.7 (-2.3, -1.1)
-1.8 (-2.2, -1.4)

1.1 (0.9, 1.3)
-0.6 (-0.7, -0.5)
0.4 (0.0, 0.8)
0.2 (-0.1, 0.5)

0.3 (0.1, 0.6)
-1.6 (-1.7, -1.5)
-2.0 (-2.3, -1.7)
-1.9 (-2.1, -1.6)

-0.5 (-0.6, -0.3)
-0.9 (-1.1, -0.8)
-1.0 (-1.2, -0.9)

-0.2 (-0.3, -0.1)
-0.3 (-0.4, -0.3)
-0.3 (-0.4, -0.2)

-0.2 (-0.3, -0.1)
-0.5 (-0.6, -0.4)
-0.6 (-0.7, -0.5)

0.3 (0.2, 0.5)
1.6 (1.5, 1.8)
1.1 (0.9, 1.2)

0.0 (-0.1, 0.1)
0.5 (0.4, 0.6)
0.3 (0.2, 0.4)

0.3 (0.2, 0.4)
1.0 (0.9, 1.1)
0.7 (0.6, 0.8)
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Hospital ownership
Private, investor-owned
Private, not-for-profit
-0.3 (-0.5, -0.2)
-0.3 (-0.4, -0.3)
0.1 (-0.1, 0.2)
Government, non-federal
1.5 (1.3, 1.8)
0.3 (0.2, 0.4)
1.0 (0.9, 1.2)
Hospital size
Small
Medium
0.9 (0.7, 1.1)
0.2 (0.1, 0.3)
0.6 (0.5, 0.7)
Large
2.4 (2.2, 2.6)
0.6 (0.5, 0.7)
1.5 (1.4, 1.6)
Hospital teaching status
Urban, non-teaching
Non-metropolitan
0.1 (-0.1, 0.4)
0.2 (0.0, 0.3)
0.0 (-0.1, 0.2)
Urban, teaching
1.4 (1.3, 1.5)
0.3 (0.3, 0.4)
0.9 (0.8, 1.0)
Year
2012
2013
-0.4 (-0.6, -0.2)
-0.1 (-0.2, 0.0)
-0.3 (-0.5, -0.2)
2014
-0.7 (-0.9, -0.5)
-0.2 (-0.3, -0.1)
-0.4 (-0.6, -0.3)
2015
-1.1 (-1.3, -0.9)
-0.4 (-0.5, -0.3)
-0.5 (-0.7, -0.4)
2016
-1.7 (-1.9, -1.5)
-0.8 (-0.9, -0.7)
-0.7 (-0.9, -0.6)
Notes:
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).
(ii) Average marginal effects (AME; days) and 95% confidence interval (CI) were adjusted for HCUP-NRD discharge weights to
generate nationally representative estimates.
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Table 8. Association of treatment strategy with aggregate number of admissions and
probability of any unplanned readmission (n = 190,563).
All admissions
AME in No. (95% CI)
Treatment strategy
SAVR
TAVR
MT
Age category
64
65-74
75-84
85
Women
Charlson comorbidity index
0-1
2-3
4-5
6
Number of inpatient procedures
0
1-2
3-4
5
Severity of illness
Minor loss of function
Moderate loss of function
Major loss of function
Extreme loss of function
Risk of mortality
Minor likelihood of dying
Moderate likelihood of dying
Major likelihood of dying
Extreme likelihood of dying
Insurance status
Medicare
Medicaid
Private
Self-pay
No charge/other
Neighborhood median household income
Bottom quartile
Second quartile
Third quartile
Top quartile
Patient urban-rural classification
Counties <249,999
Counties 250,000-999,999
Fringe counties, ≥1 million
Central counties, ≥1 million

Any readmission
AME in Prob. (95% CI)

0.3 (0.2, 0.3)
0.2 (0.2, 0.2)

0.18 (0.16, 0.19)
0.07 (0.06, 0.07)

-0.2 (-0.2, -0.1)
-0.2 (-0.2, -0.2)
-0.2 (-0.3, -0.2)
0.0 (0.0, 0.0)

-0.06 (-0.07, -0.05)
-0.04 (-0.05, -0.03)
-0.04 (-0.05, -0.03)
0.01 (0.01, 0.02)

0.2 (0.2, 0.2)
0.3 (0.3, 0.3)
0.3 (0.2, 0.3)

0.09 (0.08, 0.09)
0.13 (0.12, 0.14)
0.13 (0.12, 0.14)

0.2 (0.2, 0.2)
0.0 (-0.1, 0.0)
-0.3 (-0.3, -0.3)

0.12 (0.11, 0.12)
0.01 (0.00, 0.02)
-0.16 (-0.16, -0.15)

0.2 (0.2, 0.2)
0.1 (0.1, 0.1)
-0.4 (-0.4, -0.4)

0.05 (0.04, 0.07)
0.02 (0.01, 0.03)
-0.28 (-0.29, -0.27)

0.2 (0.1, 0.2)
0.1 (0.1, 0.1)
0.0 (-0.1, 0.0)

0.07 (0.06, 0.08)
0.04 (0.03, 0.05)
-0.05 (-0.06, -0.03)

0.0 (0.0, 0.1)
-0.3 (-0.3, -0.3)
-0.3 (-0.4, -0.3)
-0.3 (-0.3, -0.3)

-0.01 (-0.02, 0.01)
-0.12 (-0.13, -0.11)
-0.16 (-0.19, -0.14)
-0.17 (-0.19, -0.16)

0.0 (0.0, 0.0)
-0.1 (-0.1, 0.0)
-0.1 (-0.1, -0.1)

-0.01 (-0.01, 0.00)
-0.02 (-0.03, -0.01)
-0.03 (-0.04, -0.03)

0.0 (0.0, 0.1)
0.1 (0.1, 0.2)
0.1 (0.1, 0.1)

0.02 (0.01, 0.03)
0.06 (0.05, 0.07)
0.04 (0.03, 0.05)
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Hospital ownership
Private, investor-owned
Private, not-for-profit
0.0 (0.0, 0.0)
0.01 (0.00, 0.02)
Government, non-federal
0.2 (0.1, 0.2)
0.07 (0.06, 0.08)
Hospital size
Small
Medium
0.1 (0.1, 0.1)
0.05 (0.04, 0.06)
Large
0.2 (0.2, 0.2)
0.10 (0.09, 0.11)
Hospital teaching status
Urban, non-teaching
Non-metropolitan
0.0 (0.0, 0.0)
0.01 (0.00, 0.02)
Urban, teaching
0.1 (0.1, 0.1)
0.05 (0.05, 0.06)
Year
2012
2013
0.0 (-0.1, 0.0)
-0.01 (-0.02, 0.00)
2014
0.0 (-0.1, 0.0)
-0.02 (-0.03, -0.01)
2015
-0.1 (-0.1, 0.0)
-0.02 (-0.03, -0.02)
2016
-0.1 (-0.1, -0.1)
-0.04 (-0.05, -0.03)
Notes:
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).
(ii) Average marginal effects (AME; in number for total number of admissions, and in probability for any unplanned readmissions)
and 95% confidence interval (CI) were adjusted for HCUP-NRD discharge weights to generate nationally representative
estimates.
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Table 9. Total costs, inpatient days, number of admissions, and probability of any
unplanned readmission among total study population and stratified by treatment
strategy: January as index admission and 11-month follow-up (n = 32,750).
Total study
population
(n = 32,246)

SAVR

TAVR

MT

(n =10,040)

(n = 2,892)

(n = 19,314)

P-value

Total costs, mean (SD)
All admissions
41,566 (46,648) 60,759 (56,359) 67,676 (40,874) 27,704 (35,091)
< 0.01
Index admission only
29,486 (36,481) 53,474 (47,223) 56,681 (29,291) 12,921 (15,326)
< 0.01
Readmissions only
12,081 (28,229)
7,285 (25,436) 10,996 (24,361) 14,784 (29,756)
< 0.01
Inpatient days, mean (SD)
All admissions
11.9 (12.9)
12.2 (12.8)
11.3 (12.9)
11.7 (12.9)
< 0.01
Index admission only
6.8 (6.6)
9.6 (8.5)
6.8 (6.8)
5.3 (4.7)
< 0.01
Readmissions only
5.1 (10.5)
2.6 (7.9)
4.5 (9.5)
6.4 (11.5)
< 0.01
Admissions, mean (SD)
Number of all admissions
1.9 (1.4)
1.4 (0.9)
1.7 (1.3)
2.1 (1.5)
< 0.01
Probability of any readmission
0.44 (0.50)
0.27 (0.44)
0.40 (0.49)
0.53 (0.50)
< 0.01
Notes:
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).
(ii) Mean and standard deviation (SD) were adjusted for HCUP-NRD discharge weights to generate nationally representative
estimates.
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Table 10. Association of treatment strategy with total charges: total charges during all
admissions, index admission only, and readmissions only (n = 190,563).
All admissions
AME in $ (95% CI)
Treatment strategy
SAVR
TAVR
31270 (27915, 34625)
MT
-87112 (-89259, -84964)
Age category
64
65-74
-21738 (-25240, -18237)
75-84
-29995 (-33523, -26467)
85
-44772 (-48419, -41125)
Women
-299 (-1748, 1149)
Charlson comorbidity index
0-1
2-3
20377 (18597, 22158)
4-5
35410 (33092, 37728)
33920 (30583, 37257)
6
Number of inpatient procedures
0
1-2
65615 (64118, 67112)
3-4
91037 (89099, 92975)
5
123391 (121119, 125663)
Severity of illness
Minor loss of function
Moderate loss of function
22632 (20073, 25190)
Major loss of function
36482 (33565, 39400)
Extreme loss of function
29339 (25521, 33157)
Risk of mortality
Minor likelihood of dying
Moderate likelihood of dying
19919 (17754, 22084)
Major likelihood of dying
29040 (26306, 31773)
Extreme likelihood of dying
46425 (41765, 51084)
Insurance status
Medicare
Medicaid
12874 (7372, 18377)
Private
-27208 (-29715, -24702)
Self-pay
-33036 (-40128, -25943)
No charge/other
-24453 (-29901, -19006)
Neighborhood median household income
Bottom quartile
Second quartile
-3388 (-5434, -1342)
Third quartile
-4955 (-7075, -2835)
Top quartile
1645 (-608, 3897)
Patient urban-rural classification
Counties <249,999
Counties 250,000-999,999
14521 (12562, 16479)
Fringe counties, ≥1 million
24140 (21956, 26323)
Central counties, ≥1 million
63280 (60989, 65571)

Index admission only
AME in $ (95% CI)

Readmissions only
AME in $ (95% CI)

21617 (19305, 23929)
-96897 (-98205, -95590)

17076 (15415, 18737)
16321 (15213, 17429)

-4961 (-7051, -2870)
-8573 (-10683, -6463)
-15820 (-18033, -13607)
-1488 (-2397, -578)

-13283 (-15514, -11053)
-15993 (-18201, -13785)
-20292 (-22503, -18082)
743 (-2, 1487)

6051 (4924, 7178)
13962 (12554, 15369)
24215 (22093, 26338)

10928 (10045, 11811)
16721 (15587, 17856)
14252 (12650, 15854)

35287 (34488, 36085)
65769 (64791, 66747)
120131 (118780, 121482)

21201 (20352, 22051)
20136 (18903, 21370)
11995 (10476, 13514)

3913 (2010, 5816)
18175 (16031, 20318)
37867 (34834, 40899)

10772 (9339, 12205)
13282 (11682, 14883)
-13805 (-15541, -12069)

2862 (1382, 4342)
13929 (12103, 15756)
44181 (40779, 47582)

11799 (10555, 13043)
12481 (11000, 13963)
-502 (-2622, 1618)

8569 (5228, 11910)
-5150 (-6946, -3354)
-1616 (-8188, 4957)
3660 (-697, 8018)

3029 (244, 5815)
-14652 (-15843, -13461)
-19757 (-22282, -17231)
-18948 (-20990, -16906)

-476 (-1724, 772)
1017 (-295, 2329)
7984 (6576, 9392)

-1244 (-2316, -173)
-2752 (-3826, -1678)
-1860 (-3037, -682)
4977 (4021, 5934)
10133 (9057, 11208)
17463 (16328, 18599)

8916 (7623, 10208)
10999 (9633, 12365)
43968 (42500, 45437)
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Hospital ownership
Private, investor-owned
Private, not-for-profit
-74998 (-78052, -71944)
-63610 (-65459, -61761)
-12746 (-14292, -11200)
Government, non-federal
-53847 (-57792, -49902)
-57535 (-59827, -55244)
-3288 (-5256, -1319)
Hospital size
Small
Medium
25879 (23537, 28220)
15377 (13824, 16929)
6920 (5918, 7922)
Large
56194 (54081, 58307)
31141 (29732, 32551)
18387 (17443, 19331)
Hospital teaching status
Urban, non-teaching
Non-metropolitan
-39200 (-41946, -36453)
-32480 (-34283, -30678)
-5912 (-7169, -4655)
Urban, teaching
6731 (5025, 8436)
-4641 (-5743, -3538)
6108 (5272, 6944)
Year
2012
2013
-1203 (-3798, 1392)
1559 (-29, 3147)
-2465 (-3783, -1147)
2014
-4776 (-7282, -2271)
-659 (-2183, 866)
-3379 (-4712, -2046)
2015
1279 (-1205, 3762)
5138 (3619, 6658)
-2566 (-3881, -1252)
2016
519 (-1923, 2960)
7334 (5812, 8856)
-3814 (-5116, -2512)
Notes:
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).
(ii) Average marginal effects (AME; $) and 95% confidence interval (CI) were adjusted for HCUP-NRD discharge weights to
generate nationally representative estimates.
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CHAPTER 4: DISCUSSION
TAVR Increasing
In nationally-representative sample of 366,909 patients hospitalized for aortic
valve disease, IA increased 48.1% from 2012 through 2016. The likelihood of receiving
TAVR increased with an RRR of 4.57 relative to SAVR and 4.41 relative to MT, a novel
finding. However, not all patients and hospitals absorbed TAVR equally: increasing
age, female sex, severity of illness rating, high number of diagnoses, not-for-profit
hospital ownership, large hospital size, and teaching hospital status were associated
with a higher prevalence of TAVR.
Increasing patient age was associated with increased use of TAVR and
decreased use of SAVR. The potential for future growth in TAVR remains enormous
due to the high prevalence of aortic valve disease in elderly patients, the overall aging of
the US population, and anticipated expansion of TAVR to low-surgical risk patients.
Thus, from a public health perspective, knowledge of trends in aortic valve disease is
necessary to ensure adequate allocation of medical and financial resources to care for
the ever-increasing number of aortic valve patients. Our study showed a 5-year
increase of 48.1% in patients hospitalized for aortic valve disease, likely reflecting both
the aging of the population and the increased availability of TAVR. A 2013 metaanalysis of 7 studies including 9,723 patients reported a prevalence of AS of 12.4% in
patients aged ≥75 years including 3.4% with severe AS35. A 2017 meta-analysis of 56
studies in 37 countries including 42,965 patients reported the prevalence of AS to be
4.5%, comprised of 2.8% (95% CI 1.4-4.1%) of patients aged 60-74 years and 13.1%
(95% CI 8.2-17.9%) of patients aged >75 years; 19.9% (95% CI 12.8-26.9%) of AS was
classified as severe, corresponding to an estimated 781,773 (95% CI 542,9231,063,142) patients in the US, and >40% of patients did not undergo any sort valve
replacement therapy36.
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Increasing severity of illness was associated with a preference for TAVR over
SAVR. The evidence supporting this practice is historical: the pivotal randomized
controlled trials comparing mortality following TAVR and SAVR showed equipoise for
intermediate-risk patients5,6,37; for high-risk patients, the trials diverged with one showing
equipoise3 and another showing TAVR to be superior4. Recent data regarding low-risk
patients38,39 will likely lead to a future increase in TAVR and decrease in SAVR in this
patient population.

Inequitable Distribution
Patients treated at large hospitals and urban teaching hospitals were more likely
to undergo valve replacement than patients treated at small hospitals, urban nonteaching hospitals, and rural hospitals; hospitals categorized as not-for-profit and
government, non-federal were more likely to provide TAVR but not SAVR than for-profit
private hospitals. As new data and procedural techniques emerge rapidly, they are
incorporated into clinical practice unequally between different types of hospitals: in our
study, the rates of increase in TAVR and decrease in both SAVR and MT confirm that
large urban teaching not-for-profit hospitals are far faster to adopt novel evidence-based
practices for the treatment of aortic valve disease than their small, rural, non-teaching, or
for-profit counterparts. Trends in the care of patients with aortic valve disease require
much more research at the national level. Factors limiting access to TAVR must be
identified and rectified.

Cost and Cost Effectiveness
Among 190,563 patients with significant aortic valve disease treated from 20122016, the average 6-month inpatient costs were $59,743 for SAVR, $64,395 for TAVR,
and $23,460 for MT alone. Thus, while the SAVR and TAVR have both been shown to
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provide a survival benefit over MT for patients with severe aortic stenosis2,40, the 6month costs of either intervention clearly exceed the cost of MT.
In aggregate, the costs of SAVR, TAVR, and MT are estimated to total a
combined $10.2 billion annually in the US41. Several prior studies have examined the
costs of aortic valve disease care in selected populations. In the PARTNER trial cohort
B of inoperable patients randomized to TAVR or MT, TAVR carried a higher cost for the
initial hospitalization ($78,542 versus $42,806 respectively), but MT resulted in follow-up
costs almost twice those of TAVR ($29,289 versus. $53,621 respectively)42. In 2012,
Medicare payments for the 4083 beneficiaries undergoing TAVR totaled $215,770,200,
or a median of $49,500 (interquartile range [IQR] $36,900-64,600) per hospitalization,
barely less than the $50,400 (IQR $37,400-65,800) for propensity-matched SAVR
patients (p<0.01)43. Notably, for intermediate-risk trial patients, TAVR incurred ≈$20,000
more than SAVR in procedural costs but $11,377 less (p<0.01) in 2-year follow-up
costs44.
Across several studies, TAVR has been associated with increased procedural
costs but decreased post-procedural resource utilization in comparison to SAVR; cost
effectiveness estimates vary widely, particularly as a result of varying costs in different
healthcare systems13. Indeed, assessing cost effectiveness is much more complicated
than simply reporting raw costs. The American College of Cardiology typically defines
high value interventions as costing <$50,000 per quality-adjusted life year (QALY)45.
While our study was not able to assess quality of life, we were able to report from our
sensitivity analysis that, compared with MT, 11-month costs among all admissions were
$33,055 more for SAVR and $39,972 more for TAVR (Appendix Table 1, p<0.01). While
either valve replacement modality carries higher-up front costs than MT, as MT is
increasingly reserved for only higher-risk patients, their frequent readmissions and ongoing medical care may become more expensive than valve replacement procedures.
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Previous studies have yielded highly variable findings regarding cost
effectiveness. A 2018 hypothetical cost-effectiveness model for intermediate risk
patients in the Canadian healthcare system suggested that TAVR added 0.23 QALYs
versus SAVR at an incremental cost of $46,083 Canadian per QALY46. Conversely, a
2013 hypothetical cost effectiveness analysis for inoperable patients receiving TAVR
versus MT estimated an increase in quality-adjusted life expectancy from 1.19 to 1.93
years at an incremental cost of $99,900 per QALY47. A 2014 Spanish cost-utility
analysis of 207 high-risk patients reported a significant improvement in the costeffectiveness of TAVR when the price of TAVR devices was reduced by 30%,
highlighting the important role of this single expense in the economics of TAVR48.

Inpatient Duration and Readmission
We found that the average numbers of inpatient days across all admissions over
a 6-month period beginning with IA were 12.1 for SAVR, 10.0 for TAVR, and 9.7 for MT,
and the average number of admissions were 1.3, 1.5, and 1.7 respectively. In our first
sensitivity analysis, when we extended the follow-up period to 11 months, we observed
similar results to the main 6-month analysis. Long-term data are lacking, and further
studies must test the hypothesis that the up-front costs of SAVR and TAVR are offset by
reduced numbers of duration of subsequent readmissions, potentially making valve
replacement increasingly cost effective in comparison to MT over several years. Also,
as TAVR operators adopt minimalist practices and short hospital stays, TAVR has
become less expensive and could become even less expensive than SAVR. Arguing
against these hypotheses, an analysis of the National Cardiovascular Data Registry
(NCDR) Transcatheter Valve Therapies (TVT) Registry found an increase in all-cause
hospitalization and inpatient days in the 1 year post-TAVR compared with the 1 year preTAVR: although cardiovascular hospitalizations decreased, non-cardiovascular
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hospitalizations increased even more49. However, when excluding the cost of the TAVR
admission, inpatient costs were slightly lower in the post-TAVR year than the pre-TAVR
year.

A Field in Economic Flux
From a health systems perspective, an understanding of the costs, inpatient
days, and readmission rates associated with different aortic valve disease management
strategies is necessary to ensure that resources are appropriately apportioned to provide
care for the increasing number of aortic valve disease patients. TAVR continues to
supplant both SAVR and MT1, and the future growth potential for aortic valve therapy is
enormous given the high prevalence of aortic valve disease: aortic stenosis is present in
up to 4.5% of the population in developed countries with 19.9% classified as severe, and
>40% go without valve replacement36. Additionally, AR patients may also receive SAVR,
TAVR, or MT.
The field of aortic valve disease is in great flux at present with the continued
expansion of TAVR, and many changes in the economics of aortic valve disease can be
expected. For example, in our study, a greater percentage of TAVR patients than SAVR
or MT patients were treated in hospitals characterized as large, not-for-profit, urban
teaching, and in affluent neighborhoods, characteristics associated with more expensive
hospitalizations in general50. While we controlled for disparities in many hospital
characteristics in our estimation of costs, the profile of TAVR-capable hospitals is rapidly
changing in light of an updated National Coverage Determination by the Center for
Medicare and Medicaid Services that significantly reduced the requirements for hospitals
to perform TAVR51.
During our 5-year study period, IA costs and days decreased over time for TAVR
but remained stable for SAVR and MT. This observation likely results from the
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progressively lower risk profile of TAVR patients. However, even at the end of the study
period, TAVR was only available for patients at intermediate or greater surgical risk, with
intermediate risk approval occurring on August 18, 2016. Given this greater severity of
illness among TAVR vs. SAVR patients, we did find more readmission inpatient days
and higher readmission rates with TAVR. Looking specifically toward intermediate
surgical risk patients, among patients with minor or moderate loss of function, IA was
more expensive for TAVR that for SAVR: we may conjecture that the increased costs
relate to the higher cost of the TAVR prosthesis than the SAVR prosthesis.
The approval of TAVR for patients at low surgical risk52 will further alter the
economics of aortic valve disease. Additionally, the economic landscape may continue
to change with the results of the on-going EARLY TAVR trial (NCT03042104) studying
TAVR in severe, asymptomatic aortic stenosis and the TAVR UNLOAD trial studying
TAVR in moderate aortic stenosis (NCT02661451). Fortunately, thanks to the
availability of the HCUP NRD, this analysis may be repeated with relative ease in to
update the assessment of SAVR, TAVR, and MT costs in the future.

Strengths and Limitations
Prior studies have examined the use and economics of SAVR and TAVR, but our
novel study also includes the population treated with MT. Furthermore, our unique
January-through-June study methodology allowed us to obtain 6-months of postdischarge follow-up data for hundreds of thousands of patients with admissions for aortic
valve disease undergoing valve replacement or symptomatic with CHF, UA, NSTEMI,
and/or syncope. In contrast, most previous studies of aortic valve disease in HCUP data
have employed the NIS, which does not provide unique patient identifiers, thus rendering
it impossible to track patients across multiple admissions53-55. NIS studies can only
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examine outcomes per discharge, whereas our NRD methodology allowed 6-month
follow-up on a per-patient basis, a more relevant measure for SAVR, TAVR, and MT.
Our study methodology has several important limitations. First, ICD-9-CM codes
do not permit differentiation between AS and AR. The prevalence of moderate or severe
AR is only approximately 0.5%56, and AR therapy has changed minimally with the advent
of TAVR, so AR is unlikely to have contributed to the trends in therapy observed in this
study: the trends observed in this study are principally attributable to AS therapy.
Second, neither ICD-9-CM nor ICD-10-CM codes quantify the severity of aortic
valve dysfunction. Most patients with non-severe valve disease do not undergo valve
replacement unless SAVR is performed for moderate AS or AR at the time of another
cardiac surgery, typically coronary artery bypass grafting. Thus, we recognize the bias
that patients with less severe valvular disease will generally be classified in the MT
group. To mitigate this bias, we restricted our primary analysis to patients with a
concomitant diagnosis suggesting significant AS or AR (i.e., SAVR, TAVR, CHF, UA,
NSTEMI, and syncope): as seen in the first therapy trends sensitivity analysis, this
concomitant diagnosis eliminated 244,432 patients, 98.4% of whom received medical
therapy, suggesting that non-severe aortic valve disease was present. Of course, billing
codes cannot determine precisely what fraction of patients hospitalized for aortic valve
disease specifically had severe aortic stenosis, the only FDA-approved indication for
TAVR. Still, indications will change: the PARTNER 338 and Evolut Low Risk39 trials
demonstrated safety and efficacy of TAVR in low-surgical-risk patient; the on-going
EARLY TAVR trial (NCT03042104) is studying TAVR in severe, asymptomatic aortic
stenosis; and the on-going TAVR UNLOAD trial is studying TAVR in moderate aortic
stenosis (NCT02661451). Ultimately, we believe that, because all included patients had
both valve disease and an associated procedure or symptom severe enough to qualify
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as billing diagnoses for hospital admission, the patient populations in the SAVR, TAVR,
and MT groups were adequately comparable for a meaningful analysis.
Third, the NRD only captures inpatient data, excluding outpatient, emergency
department, and observation visits, which may contribute to overall costs.
Fourth, the NRD does not capture vital status after discharge, so the competing
risk of death may influence our observed readmission data.
Fifth, our main analyses used six months of follow-up, and some patients who
received MT during the study period may have subsequently undergone SAVR or TAVR,
although results did not change appreciably in the sensitivity analyses looking at followup to 11 months. Indeed, the population in the cost analysis was smaller than the
population in the therapy trends analysis because the cost analysis excluded from the
MT group patients who underwent SAVR or TAVR any time during the calendar year,
even after 6 months of follow-up. The rare patients undergoing balloon aortic
valvuloplasty would also be categorized as receiving MT, but this seems appropriate
given the short duration of effect of this procedure. Conclusively, despite these
limitations, this study provides important and novel information regarding the variation in
use of SAVR, TAVR, and MT in the US.

Conclusions
From 2012 through 2016, the use of TAVR increased at the expense of both
SAVR and MT. The greatest use of TAVR was associated with patients at elevated
surgical risk and hospitals that were large, not-for-profit, and urban teaching hospitals.
Expected expansion of TAVR indications portends continued growth of TAVR and
reduction in SAVR and MT. The inequitable distribution of TAVR therapy must be
addressed.
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For patients admitted with aortic valve disease, 6-month inpatient costs were
higher for treatment with TAVR than for treatment with SAVR, and both valve
replacement modalities were significantly more expensive than MT. Compared to
SAVR, IA was shorter for TAVR and MT, but 6-month readmission inpatient days and
the likelihood of readmission were greater for TAVR and MT. IA costs and days
decreased over time for TAVR but remained stable for SAVR and MT. The relative cost
effectiveness of these 3 treatment modalities requires further study.

47
BIBLIOGRAPHY
1. Goldsweig AM, Tak HJ, Chen LW, Aronow HD, Shah B, Kolte DS, Velagapudi P,
Desai N, Szerlip M, Abbott JD. The Evolving Management of Aortic Valve Disease: 5Year Trends in SAVR, TAVR, and Medical Therapy. Am J Cardiol 2019;124:763-771.
2. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb
JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE,
Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S,
Investigators PT. Transcatheter aortic-valve implantation for aortic stenosis in patients
who cannot undergo surgery. N Engl J Med 2010;363:1597-1607.
3. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb
JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani
VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D,
Pocock SJ, Investigators PT. Transcatheter versus surgical aortic-valve replacement in
high-risk patients. N Engl J Med 2011;364:2187-2198.
4. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG,
Buchbinder M, Hermiller J, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros
P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M,
Chenoweth S, Oh JK, Investigators USCC. Transcatheter aortic-valve replacement with
a self-expanding prosthesis. N Engl J Med 2014;370:1790-1798.
5. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH,
Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S,
Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL,
Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P,
Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG, Investigators P. Transcatheter
or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med
2016;374:1609-1620.

48
6. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M,
Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R,
Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E,
Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW,
Kappetein AP, Investigators S. Surgical or Transcatheter Aortic-Valve Replacement in
Intermediate-Risk Patients. N Engl J Med 2017;376:1321-1331.
7. Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ, Yzeiraj E,
Amat-Santos IJ, Tchetche D, Jung C, Fujita B, Mangieri A, Deutsch MA, Ubben T,
Deuschl F, Kuwata S, De Biase C, Williams T, Dhoble A, Kim WK, Ferrari E, Barbanti M,
Vollema EM, Miceli A, Giannini C, Attizzani GF, Kong WKF, Gutierrez-Ibanes E,
Jimenez Diaz VA, Wijeysundera HC, Kaneko H, Chakravarty T, Makar M, Sievert H,
Hengstenberg C, Prendergast BD, Vincent F, Abdel-Wahab M, Nombela-Franco L,
Silaschi M, Tarantini G, Butter C, Ensminger SM, Hildick-Smith D, Petronio AS, Yin WH,
De Marco F, Testa L, Van Mieghem NM, Whisenant BK, Kuck KH, Colombo A, Kar S,
Moris C, Delgado V, Maisano F, Nietlispach F, Mack MJ, Schofer J, Schaefer U, Bax JJ,
Frerker C, Latib A, Makkar RR. Transcatheter Aortic Valve Replacement in Pure Native
Aortic Valve Regurgitation. J Am Coll Cardiol 2017;70:2752-2763.
8. Abdelghani M, Cavalcante R, Miyazaki Y, de Winter RJ, Tijssen JG, Sarmento-Leite
R, Mangione JA, Abizaid A, Lemos PA, Serruys PW, de Brito FS, Jr. Transcatheter
aortic valve implantation for mixed versus pure stenotic aortic valve disease.
EuroIntervention 2017;13:1157-1165.
9. Barreto-Filho JA, Wang Y, Dodson JA, Desai MM, Sugeng L, Geirsson A, Krumholz
HM. Trends in aortic valve replacement for elderly patients in the United States, 19992011. JAMA 2013;310:2078-2085.
10. Grover FL, Vemulapalli S, Carroll JD, Edwards FH, Mack MJ, Thourani VH, Brindis
RG, Shahian DM, Ruiz CE, Jacobs JP, Hanzel G, Bavaria JE, Tuzcu EM, Peterson ED,

49
Fitzgerald S, Kourtis M, Michaels J, Christensen B, Seward WF, Hewitt K, Holmes DR,
Jr. 2016 Annual Report of The Society of Thoracic Surgeons/American College of
Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol 2017;69:12151230.
11. D'Agostino RS, Jacobs JP, Badhwar V, Fernandez FG, Paone G, Wormuth DW,
Shahian DM. The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2019
Update on Outcomes and Quality. Ann Thorac Surg 2019;107:24-32.
12. Hawkins RB, Downs EA, Johnston LE, Mehaffey JH, Fonner CE, Ghanta RK, Speir
AM, Rich JB, Quader MA, Yarboro LT, Ailawadi G, Initiative IftVCSQ. Impact of
Transcatheter Technology on Surgical Aortic Valve Replacement Volume, Outcomes,
and Cost. Ann Thorac Surg 2017;103:1815-1823.
13. Sud M, Tam DY, Wijeysundera HC. The Economics of Transcatheter Valve
Interventions. Can J Cardiol 2017;33:1091-1098.
14. HCUP. Introduction to the HCUP Nationwide Readmissions Database (NRD) 20102016. Accessed August 2018. https://www.hcupus.ahrq.gov/db/nation/nrd/Introduction_NRD_2010-2016.pdf.
15. Gupta T, Khera S, Kolte D, Goel K, Kalra A, Villablanca PA, Aronow HD, Abbott JD,
Fonarow GC, Taub CC, Kleiman NS, Weisz G, Inglessis I, Elmariah S, Rihal CS, Garcia
MJ, Bhatt DL. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With
Prior Coronary Artery Bypass Grafting: Trends in Utilization and Propensity-Matched
Analysis of In-Hospital Outcomes. Circ Cardiovasc Interv 2018;11:e006179.
16. Gupta T, Goel K, Kolte D, Khera S, Villablanca PA, Aronow WS, Bortnick AE, Slovut
DP, Taub CC, Kizer JR, Pyo RT, Abbott JD, Fonarow GC, Rihal CS, Garcia MJ, Bhatt
DL. Association of Chronic Kidney Disease With In-Hospital Outcomes of Transcatheter
Aortic Valve Replacement. JACC Cardiovasc Interv 2017;10:2050-2060.

50
17. Alkhalil A, Golbari S, Song D, Lamba H, Fares A, Alaiti A, Deo S, Attizzani GF,
Ibrahim H, Ruiz CE. In-hospital outcomes of transcatheter versus surgical aortic valve
replacement in end stage renal disease. Catheter Cardiovasc Interv 2017.
18. Doshi R, Patel V, Shah P. Comparison of in-hospital outcomes between
octogenarians and nonagenarians undergoing transcatheter aortic valve replacement: a
propensity matched analysis. J Geriatr Cardiol 2018;15:123-130.
19. Healthcare Cost and Utilization Project. "Cost-to-Charge Ratio Files: User Guide for
Nationwide Readmissions Database (NRD) CCRs." Rockville, MD: Agency for
Healthcare Research and Quality; 2018.
20. United States Department of Labor, Bureau of Labor Statistics. The Economics
Daily: Consumer Price Index, 2017.
21. Averill RF, Goldfield N, Hughes JS, Bonazelli J, McCullough EC, Steinbeck BA,
Mullin R, Tang AM, Muldoon J, Turner L, Gay J. All Patient Refined Diagnosis Related
Groups (APR-DRGs) Methodology Overview. Wallingford, CT: 3M Health Information
Systems, 2003.
22. 3M APR DRG Classification System and 3M APR DRG Software. Salt Lake City, UT:
3M Health Information Systems, 2017.
23. NRD Description of Data Elements Healthcare Cost and Utilization Project (HCUP):
Nationwide Readmissions Database, 2015.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis
1987;40:373-383.
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with
ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.

51
26. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin
Epidemiol 2004;57:1288-1294.
27. Cameron A, Trivedi P. Microeconometrics Using Stata. College Station, TX: Stata
Press, 2010.
28. Hosmer DW, Jr., Lemeshow SA, Sturdivant RX. Applied Logistic Regression.
Hoboken, NJ: Wiley, 2013.
29. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk
adjustment of skewed outcomes data. Journal of health economics 2005;24:465-488.
30. McCullagh P, Nelder J. Generalized Linear Models. London: Chapman & Hall/CRC,
1989.
31. Mullahy J. Much ado about two: reconsidering retransformation and the two-part
model in health econometrics. Journal of health economics 1998;17:247-281.
32. Belotti F, Dep P, Manning W, Norton E. TPM: Two-part models. Stata Journal
2015;15:3-20.
33. Deb P, Norton E, Manning W. Health Econometrics Using Stata. College Station, TX:
Stata Press, 2017.
34. Tukey JW. Exploratory Data Analysis. Reading, MA: Addison–Wesley, 1977.
35. Osnabrugge RL, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM,
Bogers AJ, Piazza N, Kappetein AP. Aortic stenosis in the elderly: disease prevalence
and number of candidates for transcatheter aortic valve replacement: a meta-analysis
and modeling study. J Am Coll Cardiol 2013;62:1002-1012.
36. De Sciscio P, Brubert J, De Sciscio M, Serrani M, Stasiak J, Moggridge GD.
Quantifying the Shift Toward Transcatheter Aortic Valve Replacement in Low-Risk
Patients: A Meta-Analysis. Circ Cardiovasc Qual Outcomes 2017;10.

52
37. Sondergaard L, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P,
Ngo AT, Olsen NT, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Olsen PS,
Thyregod HG. Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis
Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The AllComers Nordic Aortic Valve Intervention Randomized Clinical Trial. Circ Cardiovasc
Interv 2016;9.
38. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR,
Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR,
McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A,
Pocock SJ, Alu MC, Webb JG, Smith CR. Transcatheter Aortic-Valve Replacement with
a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019.
39. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser
JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH,
Teirstein PS, Zorn GL, 3rd, Forrest JK, Tchetche D, Resar J, Walton A, Piazza N,
Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H,
Mugglin AS, Reardon MJ. Transcatheter Aortic-Valve Replacement with a SelfExpanding Valve in Low-Risk Patients. N Engl J Med 2019.
40. Hannan EL, Samadashvili Z, Lahey SJ, Smith CR, Culliford AT, Higgins RS, Gold
JP, Jones RH. Aortic valve replacement for patients with severe aortic stenosis: risk
factors and their impact on 30-month mortality. Ann Thorac Surg 2009;87:1741-1749.
41. Moore M, Chen J, Mallow PJ, Rizzo JA. The direct health-care burden of valvular
heart disease: evidence from US national survey data. Clinicoecon Outcomes Res
2016;8:613-627.
42. Reynolds MR, Magnuson EA, Wang K, Lei Y, Vilain K, Walczak J, Kodali SK, Lasala
JM, O'Neill WW, Davidson CJ, Smith CR, Leon MB, Cohen DJ. Cost-effectiveness of
transcatheter aortic valve replacement compared with standard care among inoperable

53
patients with severe aortic stenosis: results from the placement of aortic transcatheter
valves (PARTNER) trial (Cohort B). Circulation 2012;125:1102-1109.
43. McCarthy FH, Savino DC, Brown CR, Bavaria JE, Kini V, Spragan DD, Dibble TR,
Herrmann HC, Anwaruddin S, Giri J, Szeto WY, Groeneveld PW, Desai ND. Cost and
contribution margin of transcatheter versus surgical aortic valve replacement. J Thorac
Cardiovasc Surg 2017;154:1872-1880.e1871.
44. Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, Herrmann
HC, Kodali S, Thourani VH, Kapadia S, Svensson L, Mack MJ, Brown DL, Russo MJ,
Smith CR, Webb J, Miller C, Leon MB, Cohen DJ. Cost-Effectiveness of Transcatheter
Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at
Intermediate Risk. Circulation 2019;139:877-888.
45. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ,
Halperin JL, Hlatky MA, Jacobs AK, Mark DB, Masoudi FA, Peterson ED, Shaw LJ.
ACC/AHA statement on cost/value methodology in clinical practice guidelines and
performance measures: a report of the American College of Cardiology/American Heart
Association Task Force on Performance Measures and Task Force on Practice
Guidelines. J Am Coll Cardiol 2014;63:2304-2322.
46. Tam DY, Hughes A, Fremes SE, Youn S, Hancock-Howard RL, Coyte PC,
Wijeysundera HC. A cost-utility analysis of transcatheter versus surgical aortic valve
replacement for the treatment of aortic stenosis in the population with intermediate
surgical risk. J Thorac Cardiovasc Surg 2018;155:1978-1988.e1971.
47. Simons CT, Cipriano LE, Shah RU, Garber AM, Owens DK, Hlatky MA.
Transcatheter aortic valve replacement in nonsurgical candidates with severe,
symptomatic aortic stenosis: a cost-effectiveness analysis. Circ Cardiovasc Qual
Outcomes 2013;6:419-428.

54
48. Ribera A, Slof J, Andrea R, Falces C, Gutiérrez E, Del Valle-Fernández R, Morís-de
la Tassa C, Mota P, Oteo JF, Cascant P, Altisent OA, Sureda C, Serra V, García-Del
Blanco B, Tornos P, Garcia-Dorado D, Ferreira-González I. Transfemoral transcatheter
aortic valve replacement compared with surgical replacement in patients with severe
aortic stenosis and comparable risk: cost-utility and its determinants. Int J Cardiol
2015;182:321-328.
49. Vemulapalli S, Dai D, Hammill BG, Baron SJ, Cohen DJ, Mack MJ, Holmes DR, Jr.
Hospital Resource Utilization Before and After Transcatheter Aortic Valve Replacement:
The STS/ACC TVT Registry. J Am Coll Cardiol 2019;73:1135-1146.
50. White C, Reschovsky JD, Bond AM. Understanding differences between high- and
low-price hospitals: implications for efforts to rein in costs. Health Aff (Millwood)
2014;33:324-331.
51. Decision Memo for Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R).
Washington, D.C.: Center for Medicare and Medicaid Services, 2019.
52. Witberg G, Lador A, Yahav D, Kornowski R. Transcatheter versus surgical aortic
valve replacement in patients at low surgical risk: A meta-analysis of randomized trials
and propensity score matched observational studies. Catheter Cardiovasc Interv 2018.
53. Sheng SP, Strassle PD, Arora S, Kolte D, Ramm CJ, Sitammagari K, Guha A,
Paladugu MB, Cavender MA, Vavalle JP. In-Hospital Outcomes After Transcatheter
Versus Surgical Aortic Valve Replacement in Octogenarians. J Am Heart Assoc
2019;8:e011206.
54. Elgendy IY, Mahmoud AN, Elbadawi A, Elgendy AY, Omer MA, Megaly M, Mojadidi
MK, Jneid H. In-hospital outcomes of transcatheter versus surgical aortic valve
replacement for nonagenarians. Catheter Cardiovasc Interv 2018.
55. Arora S, Strassle PD, Kolte D, Ramm CJ, Falk K, Jack G, Caranasos TG, Cavender
MA, Rossi JS, Vavalle JP. Length of Stay and Discharge Disposition After Transcatheter

55
Versus Surgical Aortic Valve Replacement in the United States. Circ Cardiovasc Interv
2018;11:e006929.
56. Maurer G. Aortic regurgitation. Heart 2006;92:994-1000.

